Podcasts about Abstract

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Conflict "The Positive Junk"Conflict "The System Maintains"The Beach Boys "A Day In The Life Of A Tree"Sly & The Family Stone "Hot Fun In The Summertime"War "The World Is A Ghetto"Luis Perez "Ipan In Xiktli Metzli"Alice Coltrane featuring Pharoah Sanders "Isis and Osiris"Sun Ra And His Myth Science Arkestra "Next Stop Mars"

We talked about older games last week - this week we're moving on to modern abstract games (within the last 20 years). The post Episode 399 – Room to Grow: Modern Abstract Games appeared first on The Family Gamers.

In the last of three episodes that make up the first installment of the Dairy Focus Lab's new "PaperCast" series, Dr. Jim Drackley and Dr. Phil Cardoso of the University of Illinois continue their discussion of a symposium review on nutrition strategies for improved health, production, and fertility during the transition period.Links to papers mentioned in this episodeFREE version review until July 02, 2020: Symposium review: Nutrition strategies for improved health, production, and fertility during the transition periodhttps://authors.elsevier.com/a/1b3IT50bFT94%7EPart 1 of the discussion: https://www.youtube.com/watch?v=JXV4Coi22VsPart 2: https://www.youtube.com/watch?v=HFyXWOHEQBUPate et al., (Abstract 237, page 165) Effects of rumen-protected methionine fed to lactating Holstein cows during a heat stress challenge on blood biomarkers harvested at 2 time points post-feeding.https://www.adsa.org/Portals/0/SiteContent/Docs/Meetings/2019ADSA/2019ADSA_Abstract_Book.pdf?v20190715Dahl et al., Effects of late-gestation heat stress on immunity and performance of calves.https://www.ncbi.nlm.nih.gov/pubmed/26805989Hans Stein webpagehttps://nutrition.ansci.illinois.edu/feed-ingredientsDiscover conferencehttps://www.adsa.org/Meetings/39th-Discover-Conference

Dr. Phil Cardoso and Dr. Adam Lock of Michigan State University discuss Dr. Lock's recent study on the effect of supplementing two major fatty acids, palmitic and oleic acid, in different ratios on milk production in high-, medium- and low-producing cows.Links to papers mentioned in this episodeWestern et al. 2020, Milk production responses to altering the dietary ratio of palmitic and oleic acids varies with production level in dairy cows. DOI: https://doi.org/10.3168/jds.2020-18936 https://pubmed.ncbi.nlm.nih.gov/33069410/de Souza et al. 2019, Altering the ratio of dietary C16:0 and cis-9 C18:1 interacts with production level in dairy cows: Effects on production responses and energy partitioning. DOI: 10.3168/jds.2019-16374https://pubmed.ncbi.nlm.nih.gov/31495626/Lock et al. 2006, Concepts of fat and fatty acid digestion in ruminants. https://www.researchgate.net/publication/266499830_Concepts_of_fat_and_fatty_acid_digestion_in_ruminantsBurch et al 2020, Milk production responses of dairy cows to fatty acid supplements with different ratios of palmitic and oleic acid in low- and high-fat basal diets. Abstract #175 in https://www.adsa.org/Portals/0/SiteContent/Docs/Meetings/2020ADSA/ADSA2020_Abstracts.pdf?v20200708.

Click on Image Above to View Sermon Video

Maximal lactate accumulation rate (ċLamax) has gained increased scientific interest in international literature as a promising augmentation of metabolic profiling. In order to recommend its application in science/practice, evidence on its reliability and specificity is crucial. Accordingly, this abstract summarizes two chapters of a recently submitted invited review article covering its current evidence and future directions for exercise testing and training. A total of N=48 peer-reviewed Journal articles in English language were aggregated in this review.Here the Abstract as .pdf:https://dshs-koeln.sciebo.de/s/PWHF4FMtyXX9APOHere a Playlist to all #sciencesnackshttps://open.spotify.com/playlist/10RidgFbWxpq2Uo7ieF84V?si=MbLfAgYMR4aD_AyHzR4Cfg&pi=QSKvlxDxSRi1XHere all guest episodes:https://open.spotify.com/playlist/2KAIQpuFMv21jKYqeBA3zy?si=jjmr2JycTE2Q1Vm9Y16LMA&pi=39X3URPuQxemdYou can support this podcast here!

Notice that the more attention is in abstraction, the harder things feel. More abstract, more problems. Really, all problems are abstractions. You can't find a problem outside of abstraction.Me-and-my-life is the ultimate abstraction. When we live with attention there, as we so often do, life feels extremely hard. Even when it's good, it's not that The post EP357: More abstract, more suffering appeared first on Dr. Amy Johnson.

Sall Cosenza's painting of Arizona is a vivid tribute to the state's untamed beauty and cultural richness. With a masterful blend of warm earth tones and bold, expressive strokes, she captures the striking contrast between the sun-drenched desert plains and the deep shadows cast by towering rock formations. Her canvas tells a story of Arizona's soul—from the iconic saguaro cacti reaching skyward to the mesmerizing glow of a desert sunset. Cosenza's artistic vision brings out the timeless stillness and spiritual energy of the Southwest, inviting viewers to feel the heat of the land, the silence of the open sky, and the deep connection between nature and place. Hosted on Acast. See acast.com/privacy for more information.

Episode 5 of Ways of Knowing -- Season 2, an audio series about the humanities. Made by The World According to Sound and The University of Washington. This episode features the work of professor of Math and the Comparative History of Ideas, Jayadev Athreya.

Dr. John Sweetenham shares highlights from Day 5 of the 2025 ASCO Annual Meeting, including data from large trials in advanced malignant melanoma and mCSPC plus a new approach to first-line treatment for patients with multiple myeloma who are not transplant eligible. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 5 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. The selected abstracts from this final day of ASCO25 include important new data from large, randomized trials in patients with advanced malignant melanoma and patients with metastatic castration-sensitive prostate cancer, as well as a new approach to the first-line treatment of patients with multiple myeloma who are not transplant eligible.  Starting with LBA9500, this study was conducted in patients with completely resected stage III or IV malignant melanoma and compared the combination of relatlimab plus nivolumab versus nivolumab alone in this population. The study, named the RELATIVITY-098 trial, was presented by Dr. Georgina Long from the University of Sydney, Australia. In her introduction to the study, Dr. Long explained that the current standard of care for adjuvant therapy of resected stage III/IV melanoma is with PD-1 monotherapy with nivolumab, but that about 50% of patients will suffer from a subsequent relapse. In the first-line setting in patients with advanced or unresectable melanoma, the combination of nivolumab with the LAG-3 inhibitor, relatlimab, has been previously shown to improve progression-free survival in the RELATIVITY-047 trial. The current study evaluated this same combination in the adjuvant setting. More than 1,000 patients from 24 countries were randomized to receive either nivolumab alone (546 patients) or the combination of nivolumab with relatlimab (547 patients). Both treatments were given for a maximum of 1 year or until progression of disease, unacceptable toxicity, withdrawal, or death. Various biomarker studies were also undertaken including LAG-3 and PD-1 expression on CD8-positive T cells. The primary endpoint of the study was relapse-free survival, and Dr. Long reported that this was the same in both arms of the study. For example, at 24 months, the relapse-free survival was 64% in the monotherapy arm compared with 62% in the combination arm. The hazard ratio was 1.01 and the P value was 0.928. Metastasis-free survival was also identical in both arms. No benefit was observed for the combination in any of the prespecified subgroups. No new toxicity signals emerged compared with the RELATIVITY-047 trial. Interestingly, the baseline surface expression of LAG-3 and co-expression of LAG-3 and PD-1 on CD8 T cells in the 098 adjuvant trial were lower than in the 047 advanced disease trial, perhaps explaining why the combination did not confer benefit over nivo alone in the adjuvant setting. This is an important result, demonstrating that results from one clinical setting cannot always be extrapolated to another. Although the combination has gained some use in the adjuvant setting, this study clearly demonstrates that more drug in this situation is no better and that monotherapy remains the current standard of care. Results from the AMPLITUDE trial for patients with metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair (HRR) genes, in LBA5006, were presented today by Dr. Gerhardt Attard from University College London, UK. This international, multicenter study evaluated the combination of the selective PARP inhibitor, niraparib, in combination with abiraterone acetate and prednisone. The same combination has been previously shown to improve outcomes in castration-resistant metastatic prostate cancer harboring BRCA mutations in the MAGNITUDE study. The current trial included patients with castration-sensitive disease with HRR mutations including BRCA1/2. Six hundred and ninety-six patients were randomized between niraparib, abiraterone, and prednisone plus androgen deprivation therapy, or the same combination with placebo instead of niraparib. Permitted prior therapies included no more than 6 months of prior androgen deprivation therapy and the use of docetaxel, or prior palliative radiation therapy. The primary endpoint of the study was radiographic relapse-free survival. Dr. Attard reported that the risk for radiographic progression-free survival in the whole population was significantly reduced by 37% with niraparib and abiraterone acetate plus prednisone compared with the placebo arm. The radiographic progression-free survival risk reduction with niraparib in the prespecified BRCA1/2 subgroup was 48% and reached statistical significance compared with the placebo arm. The secondary endpoint of time to symptomatic progression was also improved with niraparib in the HRR population and the BRCA1/2 subgroup. There was a trend for overall survival favoring the niraparib combination. However, the overall survival data were immature at this first interim analysis and did not yet reach statistical significance. No new safety concerns emerged with the toxicity data consistent with the MAGNITUDE study. Less than 5% more of the patients on the experimental arm discontinued treatment in comparison to the control arm. The authors conclude that the AMPLITUDE study results support the use of niraparib, abiraterone, and prednisone as a new treatment option for patients with metastatic castration- sensitive prostate cancer and BRCA and homologous recombination repair gene alterations. The results certainly support this conclusion and are potentially practice-changing. Turning to hematologic malignancies, my final selection from today's presentations is Abstract 7504, presented by Dr. Hang Quach from St Vincent's Hospital, Melbourne, Australia, and describes a novel combination of elranatamab, daratumumab, and lenalidomide in patients with newly diagnosed multiple myeloma who are not transplant-eligible – the so-called MagnetisMM-6 trial part 1. Elranatamab is a novel bispecific T-cell engaging antibody directed against BCMA and CD3, which has previously been approved for certain patients with relapsed and refractory multiple myeloma. In the present study, this was combined with lenalidomide and daratumumab in newly diagnosed patients. The report today describes the dose-finding phase of this study, which was part 1, specifically addressing so-called dose level ‘G', comprising elranatamab 76mg subcutaneously every 4 weeks plus daratumumab 1800mg subcutaneously and lenalidomide 25mg given orally. Thirty-seven patients were entered at this dose level, of whom 32 were on treatment at the time of analysis. Early response data show an overall response rate of 97.3%. With median follow up of 7.9 months, the current CR rate is 27% with a VGPR rate of almost 68%. The most frequent toxicities were hematologic, with neutropenia observed in 75%. Some cytokine release syndrome was observed in about 60% of patients, but none was greater than grade 2. The authors conclude that this combination is active in untreated multiple myeloma, with manageable toxicity and evidence of responses which appear to deepen over time. The dose-finding component of this trial is continuing and will subsequently progress into a phase 3 trial based on the data from the current study. This will compare daratumumab plus lenalidomide with the same combination plus elranatamab in previously untreated patients. That concludes our special coverage from the 2025 ASCO Annual Meeting. Thanks for listening and we hope you have enjoyed listening to our top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

Stormzy "First Things First"Andy Stott "On Oath"Fatima Al Qadiri "10-34"M.I.A. "20 Dollar"Boards of Canada "Rue the Whirl"Flying Lotus "Galaxy In Janaki"Primal Scream "Higher Than The Sun (A Dub Symphony In Two Parts)"Coil "Teenage Lightning 2005"SD Laika "Don't Know"Chief Keef "Twelve Bars"Fabio Frizzi "Fatti Misteriosi"Flying Saucer Attack "Wish"Deerhunter "Octet"

Special guest Rob Mitchell from Abstract Orchestra talks about their work with Guilty Simpson, Slum Village and more, plus new label Abstract Records.Pan Amsterdam talks new album Confines, dedicated to his dad. Lafayette Stokely is over in the UK for the first time and JoeJas has UK dates too. Naomi Kalu is a powerful new Mancunian singer / songwriter, and producer/rapper Arshaq Malik talks his new work.

A new track by DJ Habett from the album "Nach Mitternacht" (2025-06-03). Tags: Triphop, Attic, Tired, Beats, Chillout, Laidback, Abstract, Moods, Deep CC(by). Production notes: Then again, laidback introduction, longer than it should have been. Two sessions on different days

Los Dres. Fernando Aldaco y Homero Fuentes, oncólogos médicos mexicanos, comparten su análisis de los estudios más relevantes presentados durante el cuarto día de la Reunión Anual 2025 de la Sociedad Americana de Oncología Clínica, celebrada en Chicago, con base en la información disponible al momento de esta grabación.Los trabajos comentados son: Abstract #9510CheckMate 214 (Abstract #4505)CheckMate 816 (abstract #LBA8000)NeoADAURA (abstract #8001)IMforte (abstract #8006)DeLLphi-304 (abstract #LBA8008)PROSTest (abstract #5107)STAMPEDE (abstract #5001)BULLSEYE (abstract #5009)VIOLET (abstract #5010)Abstract #5013NeoCARHP (abstract #LBA500)Destiny-Breast09 (abstract #LBA1008)Fuentes:Abstracts presentados en el marco de la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO®) de 2025, Chicago, IL, EE.UU.

This week is devoted to older, classic abstract games. You probably know how to play these timeless games already, and have some of them relegated to the back corner of your shelves or your closet. The post Episode 398 – Room to Grow: Classic Abstract Games appeared first on The Family Gamers.

Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer and a virtual reality psychosocial intervention for patients undergoing hematopoietic stem cell transplantation. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 4 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. Today's selection features reports of 3 randomized trials in very different clinical settings: maintenance therapy in extensive small cell lung cancer (SCLC), upfront surgery in advanced ovarian cancer, and a supportive care intervention for patients undergoing hematopoietic stem cell transplantation. The first of these studies, Abstract 8006, was presented by Dr. Luis Paz-Ares from the University Hospital [October 12] in Madrid, Spain, and reports the primary results of the IMforte trial. This was a phase 3 trial evaluating the combination of lurbinectedin and atezolizumab as first-line maintenance therapy in patients with extensive small cell lung cancer. Despite some improvements in the first-line treatment of extensive small cell lung cancer with the use of checkpoint inhibitors in combination with platinum-based chemotherapy, most of the patients experience early disease progression and long-term survival remains very limited. This provides a rationale for considering a maintenance intervention. Lurbinectedin is an alkylating agent and transcription inhibitor [that is] already approved in the United States for patients with relapsed/refractory metastatic SCLC following platinum-based chemotherapy. It has been shown to synergize with immune checkpoint inhibitors in pre-clinical studies and has also been evaluated in early-phase clinical trials. The IMforte trial is a global, randomized trial in which patients are initially treated with atezolizumab, and those patients who do not progress on induction therapy are then randomized to maintenance therapy with atezolizumab alone or atezolizumab with lurbinectedin. The primary endpoints of the study were progression-free and overall survival. Four hundred and eighty-three patients were randomized and at a median follow-up of 15 months, the median progression-free survival for patients who received the combination was 5.4 months and the median overall survival was 13.2 months. This compares with 2.1 and 10.6 months, respectively, in patients who received atezolizumab only. The lurbinectedin and atezolizumab combination was generally well-tolerated, with no new or unexpected safety signals. The benefit was consistent in magnitude across all the relevant patient subgroups. This is the first phase 3 study to show a progression-free and overall survivial improvement with first-line maintenance in extensive stage SCLC and the result is likely to be practice-changing, establishing a new standard of care in this tough-to-treat disease. Next up is LBA5500, presented by Dr. Sven Mahner from LMU University in Munich, Germany. This describes the results of the TRUST study, a randomized trial of upfront surgical therapy in advanced ovarian cancer. As background, total macroscopic tumor resection with maximal effort cytoreductive surgery is the cornerstone of treatment in patients with advanced ovarian cancer. The optimal timing of such surgery remains controversial, whether it's more beneficial as a primary cytoreductive surgery before chemotherapy or in the form of interval cytoreductive surgery after 3 cycles of neoadjuvant chemotherapy. Previous studies have addressed this issue, but results have been confounded by issues of patient and center selection. The TRUST study is a randomized, international, multicenter phase 3 trial that compares the outcomes of the timing of surgery in surgically fit patients with seemingly resectable FIGO stage IIIB/IVB ovarian, tubal, and peritoneal carcinoma. To ensure consistent and adequate surgical quality, participating centers in the trial were required to obtain accreditation and undergo an onsite quality assurance review. This included assessment of infrastructure, surgical proficiency, complete resection rates, and surgical volume. Seven hundred and ninety-seven patients with advanced ovarian cancer were randomized to undergo surgery prior to therapy with 6 cycles of carboplatin and paclitaxel along with bevacizumab and a PARP inhibitor, or to have the surgery between the third and fourth cycle of the same systemic therapy. Of the initial 797 patients, 688 comprised the intent-to-treat population, of whom 345 received primary cytoreductive surgery and 343 received neoadjuvant chemotherapy followed by interval cytoreductive surgery.  The results show that patients undergoing primary surgery had significantly improved progression-free survival compared with those who had interval cytoreductive surgery (median progression-free survival was 22.1 months versus 19.7 months). No difference in overall survival was observed between the 2 arms of the study.  This is the first study to show a benefit for primary cytoreductive surgery, although the progression-free survival improvement was not reflected in an overall survival difference. A subgroup analysis for patients who underwent complete cytoreduction suggests a progression-free survival and survival benefit, although it isn't clear to me that the study was powered for this endpoint. Nevertheless, these are very difficult studies to perform, and the investigators should be congratulated for this robustly conducted clinical trial. Today's final abstract is 1504, presented by Dr. Hermioni Amonoo from Harvard Medical School. The trial evaluated BMT-VR, a virtual reality psychosocial intervention for patients undergoing bone marrow transplantation. This randomized trial included adult patients undergoing autologous and allogeneic transplantation. The BMT-VR platform included, among others, modules addressing psychoeducation, coping, acceptance, and gratitude. BMT-VR patients were provided with VR headsets and completed all modules during their hospitalization. Patient-reported outcomes were then assessed at 2, 4, 12, and 24 weeks post-BMT. Use of the VR tool was tracked during hospitalization. Control patients received usual care during their hospital stay and were then assessed at the same intervals post-BMT.  Eighty evaluable patients were randomized, 39 to BMT-VR and 41 to usual care. Completion rates for the BMT-VR modules were high [at] around 70-75%.  Patients who received the BMT-VR intervention experienced significantly improved anxiety, quality of life, and coping at 4 weeks post-BMT. In the longer term, sustained benefits were seen at 24 weeks for some endpoints including quality of life, with some benefits, including for depression and PTSD symptoms, improving longitudinally over the study period. These data are preliminary and will need to be confirmed in larger multicenter studies, but this trial demonstrates the feasibility of using virtual interventions in our patients and also provides intriguing preliminary data that they may be effective. Thanks for listening to today's report and I hope you will join me again tomorrow to hear more top takeaways from the final day of ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:     Dr. John Sweetenham       Follow ASCO on social media:      @ASCO on Twitter     @ASCO on Bluesky     ASCO on Facebook     ASCO on LinkedIn       Disclosures:    Dr. John Sweetenham:     No relationships to disclose 

The letter of Romans strengthened the ancient church, brought reformation to the dark ages, has brought hope for 2000 years, and can change your life!This week Pastor Joel continues Part 2 of his message series in the book of the Bible called Romans, “Bold Faith That Wins”. This week, Joel continues to look at one of the most controversial texts in the Bible, Romans chapter 9. In verses 14-29 we see a two-fold reminder: 1) Our perception does not determine reality, particularly when it comes to justice. 2) And that the universe does not revolve around me. Remember who you are, who God is, who God makes us to be, and what could have been. This is a special four part series that will span the year of 2025.LINKS + RESOURCES FROM THIS EPISODE:• Recommended reading for this series• The Abstract of Principles, 1859; Westminster Confession, 1646; Baptist Faith and Message, 1963, 2000; Hymn “Pass Me Not, O Gentle Savior”; C.S. Lewis; Christopher Watkin; Tim Keller; A.A. Hodge• Download the free study guide by visiting and clicking on the button "Download Study Guide"⁠• Find a complete transcript here• Scripture References: Romans 9, verses 14-29; Romans chapters 1-3; Exodus 7, verses 3-4• Find out more about Covenant Church at ⁠covenantexperience.com

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

Abstract anatomy art on the walls or bumping Pitbull every Friday are just a couple ways ATs turn the clinic into a home. ATs share their stories of the good, the bad, and the unique things about their athletic training clinic/facility/room.Featuring stories from Jackson B, Jessica J, Marc W, Marissa S, Meghan M, Courtney P, Miguel M, Alex S, Zoe H, a Kool one from Kevin, Alberto H, Mick H, & many more! --AT CORNER FACEBOOK GROUP: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/groups/atcornerpodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram, Website, YouTube, and other links: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠atcornerds.wixsite.com/home/links⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠EMAIL US: atcornerds@gmail.comSAVE on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbridge⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: Use code ATCORNER to get $101 off your subscriptionWant to host a podcast like ours? Use our link to sign up for Zencastr, the service we use to record our interviews: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://zencastr.com/?via=atcorner⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Music: Jahzzar (betterwithmusic.com) CC BY-SA---Sandy & Randy

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

Let's practice some common Spanish abstract nouns, including nombre, tipo, historia, and poco. Practice all of today's Spanish for free at LCSPodcast.com/74  

Send us a textIn this episode, we delve into the practice of Sydney-based artist Kyle Murrell, whose abstract works explore the tension between structure and meaning. A 2013 Honours graduate of the National Art School, Murrell has garnered accolades including the John Olsen Prize for Figure Drawing and the Elioth Gruner Prize for Landscape Painting . His process is rooted in drawing, serving as both exploration and regeneration, leading to paintings that deconstruct and obscure subjects through layered mark-making .Murrell's commitment to abstraction earned him the 2019 Defiance Award, granting a residency with the Nock Art Foundation in New Zealand . Represented by Defiance Gallery, his recent exhibitions include New Paintings and the upcoming Always At Every Moment (31 May – 21 June 2025) . Join us as we discuss his evolving practice, the role of repetition, and how drawing sustains his creative journey.Thanks Kyle

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Conflict Management and Resolution with Destiny F. Chau MD, FAAP, MSLOD, ACC

While other L2s fight technical battles, Abstract is creating something entirely different: a "digital Disneyland" that's all about fun.In today's episode, we chat with Luca Netz and Michael Lee "Cash Bowie," to explore how this playful approach is driving real traction:- Portal is bringing 25,000+ users to quality apps in a snap- Builders with solid monetization are generating $500K+ monthly- The Pudgy Penguins playbook is catching the eye of top global brandsFrom distribution to consumer crypto, and everything in between, you'll get the full picture of the Abstract playbook.Let's jump in.---Newton is the trust layer for autonomous finance. Smart. Secure. Verifiable. Built for a future where AI agents replace apps and interfaces. Learn more here: https://www.magicnewton.com/----

Our Abstract Series returns with an absolute classic. This one is as abstract as it gets! It's “Abstract Color Blasts!” on this week's TrekRanks! What's an “Abstract Color Blast!” you ask? Well, listen in and figure it out with our panel of host Jim Moorhouse and expert color analysts Ross Webster and Anika Dane, who come at this topic from every angle. One thing we learn for sure is that an “Abstract Color Blast!” can literally come from anywhere and be anything in Star Trek! This is a colorful conversation you will not want to miss! Episode Rundown: Diagnostic Cycle: Where we briefly get into the details of defining the show's specific topic and run through our “Abstract Series” roll call of 10 previous topics! Prime Directive: Each guest on this week's panel reveals exactly how they narrowed down their list and made their final choices. The Order of Things: All the picks are revealed with the TrekRanks' original “Five words and a hashtag” summary, along with one episode that helps frame their choice. Secondary Systems: For a few extra picks that just missed our final list. Regeneration Cycle: The panel recaps their picks and we dissect some of the interesting statistical anomalies that arose from the discussion (including our ROY G BIV breakdown). Temporal Inversion: We flashback to a previous episode of TrekRanks and relay a voicemail from one of our listeners. If you have your own picks you would like to relay to us, please hail us at 757-828-RANK (7265) and record your own personal TrekRanks log to let us know your Abstract Color Blasts! (Or you can record it yourself and just DM us @TrekRanks.com on Bluesky.) Your comments could be used as part of a Temporal Causality Loop on an upcoming episode (and might get you a chance to be a guest on a future episode, too). And don't forget to check out TrekRanks.com for our entire back catalog of episodes and a detailed rundown on every episode of Star Trek ever.      

Click on Image Above to View Sermon Video

  The Ruckus Report Quick take: International school leader Jennifer Bertram reveals how trusting your intuition can lead to unexpected leadership opportunities, and how joining a supportive community of fellow leaders transforms professional growth. Meet Your Fellow Ruckus Maker Originally from Canada, Jennifer's teaching journey began in Montevideo, Uruguay, followed by many years at Escola Americana de Campinas, Brazil. She transitioned to administrative roles including Secondary Dean of Students and Assistant Principal. Jennifer then served as Middle School Principal at the American International School of Dhaka for five years before moving to American International School Chennai with her family. Breaking Down the Old Rules

Slam this button to send us a message! All wrestling opinions welcome!On this edition of the Sit Down Marks Podcast, DB Sits Down with Independent Professional Wrestler, The Problem Solver, Xac Abstract. Xac talks his grind in wrestling so far, tours in Mexico & Japan & his wrestling roots & much more! Available on YouTube & Facebook. Audio Available on Spotify, Apple Podcasts, Audible, iHeart Radio, Sportzwire Radio & More! (Episode 159) Buy the show a coffee! Sit Down Marks! Merch SportzWire Radio Hall of Fame Podcast!! Want to Advertise or Market Your Product or Service to our Fanbase? Email dbonthemic@yahoo.com or Follow @SitDownMarks on Social Media and Message us there! #SpreadTheGoodWordofWrestling

Click image above to watch video.

01.James Hype - Don't Wake Me Up (Vibe Chemistry Remix) 02.Foor & Effie - Fire 03.Tantrum Desire, Ayah Marar - Something Real 04.Phaze - Darkest Hours 05.Flowidus & Cecelia - Fever Thoughts 06.Grafix & Nu-La - Vital Signs 07.Evergreen - Dundie 08.Plago - Pozovi Menia 09.Maduk - See It Through 10.Jurassic, DJ 007 - Remembering 11.sless, Loboski & Veronica Bravo - Heart Less 12.Martin Garrix, Mesto - Limitless (Arcando Remix) 13.Sicknote - Shock 14.Madface - Mugeni 15.T-Trider - To The Limit 16.Feed the Fire - Turn Up 17.TURNO/Riko Dan - Outta Order 18.Ekko & Sidetrack - Le Push 19.Zardonic & Reebz - Bitter (AVERTED Remix) 20.Karacha - I Chose the Life 21.Toronto Is Broken, Reebz & Sebotage - SOMEWHEREIBELONG 22.Gancher & Ruin - PSYOP 23.Emzee & Yimura - SlaughterHouse 24.KNARS - Where Is Your Head At 25.Imanu/Flux Pavillion/Tasha Baxter - Kintsugi 26.Dj Diesel & Ivory feat. Shaquille O'Neal - Run It 27.Donny - Life (DJ Hidden Remix) 28.Audio & Donny - Horribly Ribbed (Zombie Cats Remix) 29.Mayel - Diversion 30.NERV3 - Construct 31.Joe Ford, Task Horizon, The Velvet Effect - Where Is The Moon? 32.2Whales - Hrupen 33.2Whales - Dark Sun 34.Dizlunr - Over the Horizon 35.Benny V, K-Warren, Haley McCabe - You Are 36.Capital Dogz & UZI - Binary Star 37.XHL & Monyu - Fission 38.Andy Pain - Full Moon 39.Moonaddict - Shuffle the Deck 40.Holographic - Pharaoh 41.DannyLO - Whiskey Sour 42.Klinical, Koherent - Feelings 43.Kampion - 4U 44.Geostatic, Dub Ten - Feral Funk 45.Abstract, Freddy B - Diggin 46.Instant - Feel The Bass 47.Big Boss - This track sick bruv 48.Conrad Subs - Fatboi 49.Think Tonk, Alibi - Run to the Night 50.Rua Tui & Kathika - Lighters Up 51.Friction & Basslayerz - Shoot 52.Røki - Rico 53.Dunk - Yellow Jacket 54.Teddy Killerz/Sweetie Irie - Tonight 55.sola/Conrad Subs - Smash Up 56.Heathen - Serious Ting 57.Ponz - I Can't Change You 58.Forum - Beskar 59.Offish & Red Army - Sulfur 60.Jonny L - Long Long Time 61.Duburban - Breaking Point 62.Hyper-On Experience - Half Stepper (Madcap Remix) 63.Dom & Roland - A Life Of Chance 64.Kometa & Sonic Art - Break In 65.Offish & Evasion - Ash Cloud 66.Biorhythm - Bathed In Light 67.Quentin Hiatus - Gengar's Castle 68.Subp Yao - That Bounce 69.Fearful - Dark City 70.Bop x Chime - Dormant 71.Degs - If We Left This Earth 72.Technimatic & Ruth Royall - Time On Our Side 73.In:Most - 4EVER 74.London Elektricity - All On Top (feat. Conrad Subs & Genesis Elijah) 75.Northern Zone - People Changed 76.Askel & Elere - The Light Feels Low 77.Eastcolors - Waves (Maykors Remix) 78.ID-S - All Is Full Of Love 79.SOLR, Kr33per - YGM 80.Noiger - Tell Me Where You Go 81.Unknown Artist - Amalfi Coast Drive 82.Driverufo - Distant Shores 83.antoanesko - Mellow Tides

01.James Hype - Don't Wake Me Up (Vibe Chemistry Remix) 02.Foor & Effie - Fire 03.Tantrum Desire, Ayah Marar - Something Real 04.Phaze - Darkest Hours 05.Flowidus & Cecelia - Fever Thoughts 06.Grafix & Nu-La - Vital Signs 07.Evergreen - Dundie 08.Plago - Pozovi Menia 09.Maduk - See It Through 10.Jurassic, DJ 007 - Remembering 11.sless, Loboski & Veronica Bravo - Heart Less 12.Martin Garrix, Mesto - Limitless (Arcando Remix) 13.Sicknote - Shock 14.Madface - Mugeni 15.T-Trider - To The Limit 16.Feed the Fire - Turn Up 17.TURNO/Riko Dan - Outta Order 18.Ekko & Sidetrack - Le Push 19.Zardonic & Reebz - Bitter (AVERTED Remix) 20.Karacha - I Chose the Life 21.Toronto Is Broken, Reebz & Sebotage - SOMEWHEREIBELONG 22.Gancher & Ruin - PSYOP 23.Emzee & Yimura - SlaughterHouse 24.KNARS - Where Is Your Head At 25.Imanu/Flux Pavillion/Tasha Baxter - Kintsugi 26.Dj Diesel & Ivory feat. Shaquille O'Neal - Run It 27.Donny - Life (DJ Hidden Remix) 28.Audio & Donny - Horribly Ribbed (Zombie Cats Remix) 29.Mayel - Diversion 30.NERV3 - Construct 31.Joe Ford, Task Horizon, The Velvet Effect - Where Is The Moon? 32.2Whales - Hrupen 33.2Whales - Dark Sun 34.Dizlunr - Over the Horizon 35.Benny V, K-Warren, Haley McCabe - You Are 36.Capital Dogz & UZI - Binary Star 37.XHL & Monyu - Fission 38.Andy Pain - Full Moon 39.Moonaddict - Shuffle the Deck 40.Holographic - Pharaoh 41.DannyLO - Whiskey Sour 42.Klinical, Koherent - Feelings 43.Kampion - 4U 44.Geostatic, Dub Ten - Feral Funk 45.Abstract, Freddy B - Diggin 46.Instant - Feel The Bass 47.Big Boss - This track sick bruv 48.Conrad Subs - Fatboi 49.Think Tonk, Alibi - Run to the Night 50.Rua Tui & Kathika - Lighters Up 51.Friction & Basslayerz - Shoot 52.Røki - Rico 53.Dunk - Yellow Jacket 54.Teddy Killerz/Sweetie Irie - Tonight 55.sola/Conrad Subs - Smash Up 56.Heathen - Serious Ting 57.Ponz - I Can't Change You 58.Forum - Beskar 59.Offish & Red Army - Sulfur 60.Jonny L - Long Long Time 61.Duburban - Breaking Point 62.Hyper-On Experience - Half Stepper (Madcap Remix) 63.Dom & Roland - A Life Of Chance 64.Kometa & Sonic Art - Break In 65.Offish & Evasion - Ash Cloud 66.Biorhythm - Bathed In Light 67.Quentin Hiatus - Gengar's Castle 68.Subp Yao - That Bounce 69.Fearful - Dark City 70.Bop x Chime - Dormant 71.Degs - If We Left This Earth 72.Technimatic & Ruth Royall - Time On Our Side 73.In:Most - 4EVER 74.London Elektricity - All On Top (feat. Conrad Subs & Genesis Elijah) 75.Northern Zone - People Changed 76.Askel & Elere - The Light Feels Low 77.Eastcolors - Waves (Maykors Remix) 78.ID-S - All Is Full Of Love 79.SOLR, Kr33per - YGM 80.Noiger - Tell Me Where You Go 81.Unknown Artist - Amalfi Coast Drive 82.Driverufo - Distant Shores 83.antoanesko - Mellow Tides

Пиратская Станция предлагает ощутить поток энергии и красоты с помощью свежести и изысканности drumandbass релизов, которые мы регулярно запускаем на радио Рекорд! Эфир продолжает весенний движ и призывает присоединиться к нашему качу... GVOZD vibez: 1.James Hype - Don't Wake Me Up (Vibe Chemistry Remix) 2.Foor & Effie - Fire 3.Tantrum Desire, Ayah Marar - Something Real 4.Phaze - Darkest Hours 5.Flowidus & Cecelia - Fever Thoughts 6.Grafix & Nu-La - Vital Signs 7.Evergreen - Dundie 8.Plago - Pozovi Menia 9.Maduk - See It Through 10.Jurassic, DJ 007 - Remembering 11.sless, Loboski & Veronica Bravo - Heart Less 12.Martin Garrix, Mesto - Limitless (Arcando Remix) 13.Sicknote - Shock 14.Madface - Mugeni 15.T-Trider - To The Limit 16.Feed the Fire - Turn Up 17.TURNO/Riko Dan - Outta Order 18.Ekko & Sidetrack - Le Push 19.Zardonic & Reebz - Bitter (AVERTED Remix) 20.Karacha - I Chose the Life 21.Toronto Is Broken, Reebz & Sebotage - SOMEWHEREIBELONG 22.Gancher & Ruin- PSYOP 23.Emzee & Yimura - SlaughterHouse 24.KNARS - Where Is Your Head At 25.Imanu/Flux Pavillion/Tasha Baxter - Kintsugi 26.Dj Diesel & Ivory feat. Shaquille O'Neal - Run It 27.Donny - Life (DJ Hidden Remix) 28.Audio & Donny - Horribly Ribbed (Zombie Cats Remix) 29.Mayel - Diversion 30.NERV3 - Construct 31.Joe Ford, Task Horizon, The Velvet Effect - Where Is The Moon? 32.2Whales - Hrupen 33.2Whales - Dark Sun 34.Dizlunr - Over the Horizon 35.Benny V, K-Warren, Haley McCabe - You Are 36.Capital Dogz & UZI - Binary Star 37.XHL & Monyu - Fission 38.Andy Pain - Full Moon 39.Moonaddict - Shuffle the Deck 40.Holographic - Pharaoh 41.DannyLO - Whiskey Sour 42.Klinical, Koherent - Feelings 43.Kampion - 4U 44.Geostatic, Dub Ten - Feral Funk 45.Abstract, Freddy B - Diggin 46.Instant - Feel The Bass 47.Big Boss - This track sick bruv 48.Conrad Subs - Fatboi 49.Think Tonk, Alibi- Run to the Night 50.Rua Tui & Kathika - Lighters Up 51.Friction & Basslayerz - Shoot 52.Røki - Rico 53.Dunk - Yellow Jacket 54.Teddy Killerz/Sweetie Irie - Tonight 55.sola/Conrad Subs - Smash Up 56.Heathen - Serious Ting 57.Ponz - I Can't Change You 58.Forum - Beskar 59.Offish & Red Army - Sulfur 60.Jonny L - Long Long Time 61.Duburban - Breaking Point 62.Hyper-On Experience - Half Stepper (Madcap Remix) 63.Dom & Roland - A Life Of Chance 64.Kometa & Sonic Art - Break In 65.Offish & Evasion - Ash Cloud 66.Biorhythm - Bathed In Light 67.Quentin Hiatus - Gengar's Castle 68.Subp Yao - That Bounce 69.Fearful - Dark City 70.Bop x Chime - Dormant 71.Degs - If We Left This Earth 72.Technimatic & Ruth Royall - Time On Our Side 73.In:Most - 4EVER 74.London Elektricity - All On Top (feat. Conrad Subs & Genesis Elijah) 75.Northern Zone - People Changed 76.Askel & Elere - The Light Feels Low 77.Eastcolors - Waves (Maykors Remix) 78.ID-S - All Is Full Of Love 79.SOLR, Kr33per - YGM 80.Noiger - Tell Me Where You Go 81.Unknown Artist - Amalfi Coast Drive 82.Driverufo - Distant Shores 83.antoanesko - Mellow Tides

Yellow Swans "Untitled"John Davis "Untitled"No UFO's "Anthropomorphic Clouds of Smoke"Zelienople "More Mess"Gregg Kowalsky "VI-VII"Ilyas Ahmed "As Another"Common Eider, King Eider "Earth Liver"Jon Porras "Grey Dunes"Grouper "Cover The Windows And The Walls"

Maverick and artist Dustin Caballero explore the competitive nature of the art world, the evolution of artistic style, and the importance of creating art for oneself rather than for others. Dustin shares insights into his creative process, the challenges of navigating the art business, and the significance of community support. The discussion also touches on the impact of external factors on the art industry and the intersection of art and personal style, including sneaker culture.Rubiel Art:https://www.rubielart.comhttps://www.instagram.com/rubielartMaverick Podcast:

Click the image above to watch the sermon video.

Abstract neurographic artist Ayiana Viviana shares how reconnecting with Puerto Rico, battling inner struggles, and choosing self-trust transformed her art—and her life—with new courage, clarity, and creative depth.How a return to Puerto Rico—and a visit to an Indigenous site—recharged her spirit and creativityNeurographic art as emotional release: painting through pain, grief, and unseen feelingsListening to the second voice: surviving a mental health crisis and finding a new path through paintingDreams, risk, and reward: the story behind a $5,000 mural project and stepping into full creative worthPhilly's evolving arts scene: fighting for funding access and empowering artists at the grassroots levelOn building a slower, fuller life: why downtime, reading, and reflection now fuel her best workWant to hear more about Ayiana's early creative journey? Listen to her first conversation from 2023 here: Art and Emotion | Ayiana Viviana's Porter's Creative Exploration.This episode was recorded during a season celebrating growth, resilience, and the artists who show us what it means to turn life into art. Host: Rob LeeMusic: Original music by Daniel Alexis Music with additional music from Chipzard and TeTresSeis. Production:Produced by Rob Lee & Daniel AlexisEdited by Daniel AlexisShow Notes courtesy of Rob Lee and TransistorPhotos:Rob Lee photos by Vicente Martin for The Truth In This Art and Contrarian Aquarian Media.Guest photos courtesy of the guest, unless otherwise noted.Support the podcast The Truth In This Art Podcast Fractured Atlas (Fundraising): https://www.fracturedatlas.orgThe Truth In This Art Podcast Bluesky: https://bsky.app/profile/thetruthinthisart.bsky.socialThe Truth In This Art Podcast Instagram: https://www.instagram.com/truthinthisart/?hl=enThe Truth In This Art Podcast Website: https://www.thetruthinthisart.com/The Truth In This Art Podcast Shop: Merch from Redbubble ★ Support this podcast ★

On this episode of Banking on KC, artist Sheron Smith joins host Kelly Scanlon to share how KC's jazz influences, architectural beauty and her own emotional expression come together in her jazz, cityscape and abstract artwork. Tune in to discover:How Sheron brings historic jazz clubs and Kansas City landmarks to life with bold, expressive color.What draws her to abstract art and the versatile techniques she uses to create it.Why Kansas City's artistic community inspires and nurtures her work.How she balances creativity and entrepreneurship to build a sustainable art career.Country Club Bank – Member FDIC

This is an exciting re-release, a compilation of my conversations with abstract painters. All of these artists are smart and talented with a keen sense of how we relate to the world around us. Be sure to check out the full Eager To Know episodes for all 5 of these artists:   A New World Artist Darren Jones Jeff Cote The Choice Parade Sheila Arora Painter William Conger   Links to all 7 episodes can also be found at: eager2know.com

Pere Ubu "Chinese Radiation" Pere Ubu "Goodbye"Mirrors "She Smiled Wild"The Girls "Elephant Man"Pressler-Morgan One Plus One "You're Gonna Watch Me"15:60:75 "Behind Your Eyes"Devo "Smart Patrol/Mr. DNA"Dead Boys "Not Anymore"Dead Boys "Ain't Nothin to Do"Pagans "Dead End America"Pagans "Little Black Egg"Electric Eels "Spin Age Blasters"Electric Eels "Bunnies"Screaming Urge "Do You Think I'm Strange?"Bone Thugs-N-Harmony "For Tha Love of $ (Tha Yella Mix 9 Minutes Uv Funk)"

In this week's episode we'll cover Foundations of Metropolis, our Game of the Week, discuss Variable Setups in The School of Gaming,  and wrap it up by revealing our High-Five Abstract Games!  We also Spotlight A Gentle Rain from Incredible Dream!00:00:00 - Introductions & Awesomeness00:09:30 - Spotlight: A Gentle Rain00:19:03 - Game of the Week: Foundations of Metropolis00:49:10 - School of Gaming: Variable Setup in Board Games01:02:49 - High-Five: Abstract Games

This week we're covering anti-intellectualism: what is it, who's involved, is there room to grow? Hope you like *light* mental lifting (don't worry I'll spot you) because we're answering all these questions and more on this week's episode of Schauer Thoughts! Stop putting off those doctors appointments and go to https://Zocdoc.com/SCHAUER to find and instantly book a top-rated doctor today.  For a limited time, get Headspace FREE for 60 days. Go to https://Headspace.com/SCHAUER Articles: Anti-intellectualism  https://www.ebsco.com/research-starters/social-sciences-and-humanities/anti-intellectualism Exploring the Reasons Behind Parental Refusal of Vaccines https://pmc.ncbi.nlm.nih.gov/articles/PMC4869767/ Information Density https://publish.obsidian.md/pkc/Hub/Theory/Sciences/information+density The Development of Concrete and Abstract Thinking Patterns  Blog post but clinically reviewed by Tiffany Lovins, Licensed Mental Health Counselor (LMHC) https://calmerry.com/blog/psychology/the-development-of-concrete-and-abstract-thinking-patterns/#:~:text=Abstract%20thinking%20and%20concrete%20thinking%20are%20two,us%20to%20make%20connections%20and%20see%20patterns Cliche's - What is a cliche? https://writingcenter.unc.edu/tips-and-tools/cliches/#:~:text=What%20is%20a%20cliché?,memorable%20contributions%20to%20your%20writing Books: The Knowledge Illusion - Steven Sloman & Philip Fernbach Quoted pages: 175 - 178 Attention: Beyond Mindfulness - Gay Watson If there are any resources I mentioned that are not listed, please let me know and I'll update ASAP. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This is The Digital Story Podcast #995, April 15, 2025. Today's theme is, "Abstract Architecture." I'm Derrick Story. Opening Monologue I found myself sitting in the atrium of a Hyatt Regency looking up. I started to wonder how things would look if I were up there, looking down. What I discovered is a beautiful subject for abstract photography. I tell the story of how this all worked out on today's TDS Photography Podcast. I hope you enjoy the show.

Default deny is an old, and very recognizable term in security. Most folks that have been in the industry for a long time will associate the concept with firewall rules. The old network firewalls, positioned between the public Internet and private data centers, however, were relatively uncomplicated and static. Most businesses had a few hundred firewall rules at most. The idea of implementing default deny principles elsewhere were attempted, but without much success. Internal networks (NAC), and endpoints (application control 1.0) were too dynamic for the default deny approach to be feasible. Vendors built solutions, and enterprises tried to implement them, but most gave up. Default deny is still an ideal approach to protecting assets and data against attacks - what it needed was a better approach. An approach that could be implemented at scale, with less overhead. This is what we'll be talking to Threatlocker's CEO and co-founder, Danny Jenkins, about on this episode. They seemed to have cracked the code here and are eager to share how they did it. This segment is sponsored by ThreatLocker. Visit https://www.securityweekly.com/threatlocker to learn more about them! We wanted security data? We got it! Now, what the heck do we DO with all of it? The core challenge of security operations, incident response, and even compliance is still a data management and analysis problem. Which is why we're seeing companies like Abstract Security pop up to address some of these challenges. Abstract just released a comprehensive eBook on security data strategy, linked below, and you don't even need to give up an email address to read it! In this interview, we'll talk through some of the highlights: Challenges Myths Pillars of a data security strategy Understanding the tools available Segment Resources A Leader's Guide to Security Data Strategy eBook In the enterprise security news, new startup funding what happened to the cybersecurity skills shortage? tools for playing with local GenAI models CVE assignment drama a SIEM-agnostic approach to detection engineering pitch for charity a lost dog that doesn't want to be found All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-402